Clinical Trial

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 27, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2026-07-31 2026-04-23
minor Completion pushed: 2026-09-30 -> 2026-12-31 2026-04-23
Trial Details
NCT Number NCT06205628
Lead Sponsor ADARx Pharmaceuticals, Inc.
Collaborators: ADARx Australia Pty Ltd
Conditions Hypertension, Hypertension,Essential
Enrollment 28 participants
Start Date 2024-03-21
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-27